Clare McGrane
Biomatics Capital raises $300M fund, hires Gates Foundation global health director Mike Poole to lead neurology investments
Biomatics Capital raised a $300 million second fund to invest in 15–20 healthcare and life-sciences startups focused on innovations at the intersection of healthcare and technology, and added two partners — Dr. Mike Poole from the Bill & Melinda Gates Foundation to lead neurology-focused, data- and genomics-enabled investments, and biotech investor Errik Anderson.
98point6 raises $50M led by Goldman Sachs to expand AI‑augmented virtual primary care, totaling $86.3M raised
Seattle startup 98point6 raised $50 million in a round led by Goldman Sachs’ Merchant Banking Division, bringing total funding to $86.3 million to expand its AI‑augmented, text-based virtual primary care service and grow staff and geographic coverage.
SEngine Precision Medicine raises $3M (round now $8.2M), adds Nobel laureate Lee Hartwell and investor Elliott Burkland to board
SEngine Precision Medicine raised $3 million, bringing its current round to $8.2 million, and appointed former Fred Hutch president and Nobel laureate Dr. Lee Hartwell to its board; new investor Elliott Burkland of Bangarang Group will also join the board. The company uses its PARIS test to grow patients’ tumor cells as organoids and analyze drug combinations to personalize cancer treatment.
Receptor Life Sciences raises $29M Series A to advance inhaled dry‑powder cannabinoid medicines and start FDA IND process
Receptor Life Sciences, led by CEO Gregory Wesner, raised $29 million in its first Series A to advance an inhaler delivering dry powdered cannabinoid medicines and begin the FDA investigational new drug process while formalizing collaborations in Canada and Europe.
University of Washington spinout Split Biosciences raises $1.2M to commercialize SPLiT-seq single‑cell RNA sequencing
Split Biosciences, a University of Washington spinout founded by Charlie Roco, Alex Rosenberg, and Georg Seelig, raised a $1.2 million seed round to commercialize SPLiT-seq, a faster, higher-throughput single-cell RNA sequencing method that uses combinatorial barcoding to avoid physical cell isolation.
Stealth biotech Receptor Life Sciences raises $7.5M to develop inhalable plant-extract pharmaceuticals targeting pain, CNS and chemo side effects
Receptor Life Sciences, a stealthy Seattle-area biotech founded in 2015, raised just over $7.5 million and is developing inhalable pharmaceutical preparations derived from plant extracts to treat conditions including pain, CNS and metabolic and gastrointestinal disorders, and chemotherapy side effects. The company declined to name investors or disclose the specific plant, lists minimal public personnel, and had a USPTO appeal to trademark its name rejected.
Silverback Therapeutics raises $37.5M from OrbiMed, Celgene and Alexandria; Series A totals $47.5M as it unveils disease‑site targeting platform
Silverback Therapeutics revealed its technology that delivers systemically administered therapies which activate only at disease sites and announced an additional $37.5 million, bringing its Series A to $47.5 million from investors including OrbiMed, Celgene, and Alexandria.
Saykara raises $5M to scale AI voice assistant that cuts doctors' paperwork time by 70%
Saykara raised $5 million to scale its AI voice assistant that passively documents patient visits and reportedly cuts physicians' paperwork time by 70%, with funds to grow sales, marketing, and product features.
OncoResponse raises $40M Series B to advance five antibody-based cancer immunotherapies into preclinical and clinical trials
OncoResponse raised $40 million in a Series B to push five antibody-based cancer immunotherapy candidates into preclinical and clinical studies, bringing total funding to nearly $70 million since its 2015 launch. The company mines antibodies from cancer patients who had exceptional responses to immunotherapy to develop treatments that modulate tumor‑microenvironment immunosuppression.
Seattle Series A Deals Match Bay Area on Valuation (~$25M) and Size (~$10M) as Silicon Valley Investor Participation Doubles
An analysis of Series A rounds through July shows Seattle startups are securing similar valuations (~$25M) and deal sizes (~$10M) to Bay Area peers, and Silicon Valley investor participation in Seattle deals has more than doubled over the past decade.
TwinStrand Biosciences raises $1.2M toward $4M round to commercialize Duplex Sequencing that detects tiny DNA mutations
TwinStrand Biosciences, a University of Washington spin-out, is raising up to $4 million (having secured $1.2 million so far) to commercialize Duplex Sequencing, a method that sequences and compares both DNA strands to remove noise and detect tiny mutations invisible to standard sequencers.
ApoGen Raises $4M More in Series A to Combat Drug-Resistant Cancers, Adds Biotech Vets to Leadership
Biotech startup ApoGen raised an additional $4 million in its Series A round, totaling $11 million, to advance its development of treatments for drug-resistant cancers. The company also expanded its executive team by hiring Seattle biotech veteran Peter de Vries and added M Ventures' Investment Director Keno Gutierrez to its board.
DreamBox Learning raises $130M from The Rise Fund; Arne Duncan joins board as investor takes majority stake
DreamBox Learning raised $130 million from The Rise Fund, which will take a majority stake and add former U.S. Education Secretary Arne Duncan to DreamBox’s board; the company will use the capital to scale operations and expand its ML-driven K–8 math platform into more schools. DreamBox, used by nearly 3 million students and recently launched in Spanish in Mexico, emphasizes personalized, adaptive learning and aligned social-impact goals with its new investor.
StratoScientific raises $1.23M from angels to expand Steth IO iPhone stethoscope into EU and Canada
StratoScientific raised $1.23 million from angel investors to expand its Steth IO smartphone-based stethoscope into the EU and Canada and to fund clinical trials studying cardiovascular use cases.
Presage Biosciences raises $6M from Takeda and Celgene, names Rich Klinghoffer CEO to scale CIVO tumor microdosing platform
Presage Biosciences raised $6 million led by Takeda and Celgene to expand use of its CIVO platform, which microdoses cancer drugs into human tumors to speed early testing, and appointed Rich Klinghoffer as CEO while founder Nathan Caffo becomes a strategic advisor.
EndoGastric Solutions raises $30.5M from existing and new investors to expand commercialization of TIF GERD treatment
EndoGastric Solutions raised $30.5 million from existing and new investors to scale commercialization of its on-market treatment for chronic acid reflux (GERD), aiming to expand access to its TIF procedure for millions of patients.
Phytelligence raises $9.85M more in Series B to reach $16.8M, total funding $22.5M; headcount tops 150
Phytelligence raised an additional $9.85 million in its Series B, bringing that round to $16.8 million and total funding to $22.5 million, while doubling staff to about 150 and expanding operations across Washington and Oregon.
Viome raises $5.5M led by Physician Partners to expand gut-microbiome wellness service; total funding $26.5M
Naveen Jain’s wellness startup Viome raised $5.5 million—$5 million from Physician Partners and $500,000 from an unnamed investor—and plans to study how its gut-microbiome sequencing service can prevent, delay, or reverse costly chronic diseases. The company has nearly tripled headcount to 125 employees and has now raised $26.5 million total.
Aminex Therapeutics raises $10M ( $19M total) and launches Phase I trial of AMXT‑1501 for solid tumors; first patient dosed
Aminex Therapeutics raised $10 million, bringing its total funding to $19 million, and has begun a Phase I clinical trial of its small-molecule immunotherapy AMXT‑1501 for multiple solid tumors, with the first patient dosed in San Antonio.
Seattle Children’s spin-out MDMetrix raises $758,000 seed to build automated A/B testing for clinicians
MDMetrix, a Seattle Children’s spin-out cofounded by anesthesiologist Dan Low and engineer Matthew Goos, raised just over $758,000 in seed funding to build an automated A/B testing platform that lets doctors compare real-world data on drugs, procedures, and devices. The company incubated inside Seattle Children’s, has four full-time employees (not counting Low, who takes no salary), and Low plans to hand off CEO duties once the startup is established.
Brook.ai raises $4M seed and partners with Independent Health to deploy diabetes management platform to 380,000 members
Seattle startup Brook.ai raised a $4 million seed round to expand its digital health platform that uses real-world data and personal coaching to help people manage type 2 diabetes, and partnered with Independent Health to bring the tech to about 380,000 members.
AbSci raises $12M Series C led by Asahi Glass Co. to scale SoluPro/SoluPure biologics platform
AbSci raised an oversubscribed $12 million Series C led by Asahi Glass Co. to scale its SoluPro and SoluPure synthetic biology platforms for manufacturing complex biologics such as insulin and antibodies.
Seattle Startups Land Hundreds of Millions as Rover Raises $155M, Madrona Unveils $300M Fund; Space Needle Gets Redesigned Deck
Seattle saw a surge of startup funding across sectors—pet-care marketplace Rover raised $155M, Madrona launched a $300M fund, Outreach got $65M, and several other companies secured sizable rounds—while Getaround expanded into the city and the Space Needle unveiled a redesigned observation deck.
Nohla Therapeutics Raises $45M, Reaches $100M Total as Dilanu**bicel Advances Toward FDA Approval
Nohla Therapeutics raised $45 million in equity, bringing its total funding to $100 million as it advances dilanubicel, a cord‑blood–derived stem cell leukemia treatment, toward FDA approval. The Fred Hutch spinout has doubled headcount to 43 and moved to a new Seattle headquarters while attracting investors including Fidelity and Celgene.
Proniras launches in Seattle to develop Eli Lilly’s tezampanel, wins $89.5M BARDA contract
Proniras Corporation launched in Seattle to develop tezampanel, a seizure drug originally created by Eli Lilly, and secured an $89.5 million BARDA contract contingent on development milestones. The company also received undisclosed launch funding from several investors, will be led by co-founder and CSO Chris Toombs, and plans to explore tezampanel as both a seizure therapy and a nerve-agent antidote.